Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population

by Tamkin Ahmadzada, BE, Wendy A. Cooper, BScMed, M.B.B.S., PhD, FRCPA, Mikaela Holmes, BBiomedSc, Annabelle Mahar, M.B.B.S., FRCPA, Helen Westman, MPH, Anthony J. Gill, MD, FRCPA, Ina Nordman, M.B.B.S., FRACP, M(Med)Sc, Po Yee Yip, MbChB., FRACP, PhD, Abhijit Pal, BSc (Hons), M.B.B.S., FRACP, Rob Zielinski, FRACP, M.B.B.S., Hons, Nick Pavlakis, BSc, M.B.B.S., MMed (Clin Epi), PhD, FRACP, Adnan Nagrial, M.B.B.S., PhD, Dariush Daneshvar, MD, FRCPA, Daniel Brungs, M.B.B.S., MMed (Clin Epi), FRCPA, Deme Karikios, BSc, M.B.B.S., FRACP, PhD, Vesna Aleksova, BMedSc, Juliet Burn, M.B.B.S., FRCPA, MIAC, Rebecca Asher, MSc, Georges E. Grau, MD, PhD, Elham Hosseini-Beheshti, MSc, PhD, Glen Reid, PhD, Stephen Clarke, MD, PhD, FRACP, Steven Kao, BHB, MbChB., PhD, FRACP
Published 2020-11-01